You are here

Rituxan

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Fierce Pharma

Flag link:

Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma

Fierce Pharma

follicular lymphoma

Flag link:

FDA panel unanimously backs Celltrion's Rituxan biosimilar

FDA panel unanimously backs Celltrion's Rituxan biosimilar

Fierce Pharma

Teva Pharmaceutical

advisory panels

Flag link:

FDA reviewers endorse Celltrion's Rituxan biosimilar ahead of panel vote

FDA reviewers endorse Celltrion's Rituxan biosimilar ahead of panel vote

Fierce Pharma

advisory panels

Flag link:

Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma

Jumping ahead of AstraZeneca, AbbVie and J&J get a green light to market Imbruvica/Rituxan combo for rare lymphoma

Endpoints

non-Hodgkin's lymphoma

Waldenström’s macroglobulinemia

Flag link:

Can Celgene's latest Revlimid win reverse the company's bad-news streak?

Can Celgene's latest Revlimid win reverse the company's bad-news streak?

Fierce Pharma

clinical trials

non-Hodgkin lymphoma

Flag link:

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

Endpoints

chronic lymphocytic leukemia

Flag link:

FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

CP Wire

pemphigus vulgaris

Genentech/Roche

Flag link:

FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

Genentech/Roche

pemphigus vulgaris

Flag link:

5 Best-Selling Orphan Drugs in the U.S.

5 Best-Selling Orphan Drugs in the U.S.

Motley Fool

Teva Pharmaceutical

Bristol-Myers Squibb

Flag link:

Celltrion resubmits Rituxan candidate in US, Herceptin version to follow

Celltrion resubmits Rituxan candidate in US, Herceptin version to follow

Biopharma Reporter

Flag link:

AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely

AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely

S&P Global

Flag link:

Pfizer’s latest copycat could put the squeeze on Roche — again

Pfizer’s latest copycat could put the squeeze on Roche — again

Endpoints

Flag link:

Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals

Roche CEO Schwan concedes challenges as ‘highly, highly profitable’ drugs fall to biosimilar rivals

Fierce Pharma

Flag link:

Roche's Fight With Pfizer May Be Just The Beginning

Roche's Fight With Pfizer May Be Just The Beginning

Forbes

Flag link:

Good quarter for Roche, but competition by biosimilars concerns investors

Good quarter for Roche, but competition by biosimilars concerns investors

GoinPharma

Flag link:

Roche feeling first effects of biosimilar Rituxan

Roche feeling first effects of biosimilar Rituxan

Biopharma Dive

Flag link:

AbbVie, Roche to seek broader market for leukemia drug after trial success

AbbVie, Roche to seek broader market for leukemia drug after trial success

BioPharma Dive

clinical trials

chronic lymphocytic leukemia

Flag link:

Poor test results for Roche cloud growth prospects

Poor test results for Roche cloud growth prospects

Yahoo/Reuters

Flag link:

The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise

The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise

Endpoints

Flag link:

Pages